2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
57
Breast Neoplasms
35
Neoplasms
32
Parkinson Disease 4, Autosomal Dominant Lewy Body
26
Multiple Myeloma
24
Leukemia, Myeloid, Acute
21
Recurrence
20
Colorectal Neoplasms
17
Neoplasm Metastasis
17
Carcinoma, Renal Cell
15
Lymphoma, Non-Hodgkin
15
Ovarian Neoplasms
15
Leukemia
14
Leukemia, Lymphocytic, Chronic, B-Cell
14
Melanoma
14
Lymphoma, Follicular
12
Precursor Cell Lymphoblastic Leukemia-Lymphoma
12
Lung Neoplasms
11
Myelodysplastic Syndromes
11
Urinary Bladder Neoplasms
11
Carcinoma, Hepatocellular
10
Hematologic Neoplasms
10
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
10
Adenocarcinoma
9
Glioma
9
Lymphoma
9
Lymphoma, Large B-Cell, Diffuse
9
Lymphoma, Mantle-Cell
9
Prostatic Neoplasms
9
Stomach Neoplasms
9
Interventions
talazoparib
1
enzalutamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has announcements
×
mCRPC
×
Clear all
NCT03395197
2026-04-22
TALAPRO-2
Pfizer
Phase 3
Active not recruiting
1,054 enrolled
21 charts
1 FDA